Lantus

Lantus

insulin glargine

Manufacturer:

Kalventis Sinergi Farma
Concise Prescribing Info
Contents
Insulin glargine
Indications/Uses
DM in adults, adolescents & childn ≥2 yr.
Dosage/Direction for Use
SC Individualized dosage. Administer at any time once daily but at the same time each day. Inj sites must be rotated w/in given inj area from 1 inj to the next.
Contraindications
Special Precautions
Not for IV administration. Not the insulin of choice for the treatment of diabetic ketoacidosis. Hyper- or hypoglycaemic episodes. Intensify blood glucose & metabolic monitoring. Caution in patients in whom hypoglycaemic episodes might be of clinical relevance (eg, patients w/ significant stenoses of the coronary arteries or of the blood vessels supplying the brain as well as in patients w/ proliferative retinopathy, particularly if not treated w/ photocoagulation; patients w/ diminished warning symptoms of hypoglycaemia (eg, patients in whom glycaemic control is markedly improved, in whom hypoglycaemia develops gradually, elderly, after transfer from animal to human insulin, in whom an autonomic neuropathy is present, w/ a long history of DM, suffering from a psychiatric illness, receiving concurrent certain medications). Prolonged effect may delay recovery from hypoglycaemia. Increased susceptibility to hypoglycaemia in case of change in inj area; improved insulin sensitivity; unaccustomed, increased or prolonged physical activity; intercurrent illness; inadequate food intake; missed meals; alcohol consumption; certain uncompensated endocrine disorders; concomitant treatment w/ certain other medicinal products. Hyperglycaemia may occur under certain circumstances including omission/reduction of inj or decrease in insulin effectiveness, pen malfunction; decreased physical activity, stress situations, injuries, operations, feverish illnesses or certain other diseases; concurrent use of other medicines. Intercurrent illness. May cause insulin Ab to form. Insulin label must always be checked before each inj to avoid medication errors. May impair ability to concentrate & react when driving or using machines. Hepatic & renal impairment. Maintain good metabolic control during pregnancy in women w/ preexisting or gestational diabetes. Decrease insulin requirements during 1st trimester & generally increase during 2nd & 3rd trimesters. Lactation. Childn <2 yr. Elderly ≥65 yr.
Adverse Reactions
Hypoglycaemia. Lipohypertrophy; inj site reactions.
Drug Interactions
Enhanced blood-glucose-lowering effect & increased susceptibility to hypoglycaemia w/ oral antidiabetics, ACE-inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulfonamide antibiotics. Reduced blood-glucose-lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, oestrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics (eg, epinephrine, salbutamol, terbutaline), thyroid hormones, PIs & atypical antipyschotics (eg, olanzapine & clozapine). Potentiated or weakened blood-glucose-lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. Hypoglycemia may sometimes followed by hyperglycemia w/ pentamidine. Reduced or absent signs of adrenergic counter-regulation w/ sympatholytics eg, β-blockers, clonidine, guanethidine, reserpine.
MIMS Class
Insulin Preparations
ATC Classification
A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.
Presentation/Packing
Form
Lantus soln for inj 100 U/mL
Packing/Price
(cartridge) 3 mL x 5 × 1's; (vial) 10 mL x 1's
Form
Lantus Solostar inj 100 U/mL
Packing/Price
(prefilled pen) 5 × 1's (Rp1,343,267/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in